A patent is essentially a government license that gives
certain rights to the patent holder, excluding others from making, using, or
selling a particular product or invention without permission. According to
WIPO’s 2015 World Intellectual Property Indicators Report, there have been more
than 2.7 million patent filings worldwide since 2013 and this number has grown
significantly in recent years. The top three offices in the world have been in
China, the U.S., and Japan. According to the report, the leading technology
fields are computer technology, electrical machinery, measurement, and digital
communication, with medical technology not far behind.
International Stem Cell Corporation (OTCQB: ISCO) is a
publicly traded biotechnology company that promises to advance the field of
regenerative medicine by addressing the problem of immune-rejection. Most
recently, the company has focused its efforts on using unfertilized human eggs
to create parthenogenetic stem cells to treat severe diseases of the eyes and
nervous system, including diseases such as Parkinson’s. The company is careful
to protect its associated intellectual property.
International Stem Cell Corporation protects its technology
worldwide by filing and holding patent applications for its more specific stem
cell lines, methods of production, and various research methods. So far, ISCO
has 16 issued patents and 91 pending patents across 15 patent families, as well
as a licensed portfolio of 25 patents or patents applications across eight
patent families related to its skin care products. Most of International Stem
Cell Corp.’s patents are filed internationally, covering the U.S., Canada, and
a wide range of other industrialized countries.
The company’s technology strengths are backed up by a
carefully chosen team of managers and scientists. ISCO’s directors, executive
managers, and scientific advisors have been selected to benefit the company’s
business and science related operations. Each person is skilled in particular
aspects of corporate management or biotechnology, with executive managers
specializing in systems analysis, strategic planning and corporate management,
as well as financial management, accounting, medical genetics, embryology, and
stem cell biology. This level of combined experience enables ISCO to function
positively in every aspect of its business.
For more information, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
